Wall Street analysts expect Syneos Health, Inc. (NASDAQ:SYNH – Get Rating) to report earnings per share of $0.96 for the current fiscal quarter, Zacks Investment Research reports. Five analysts have provided estimates for Syneos Health’s earnings. The highest EPS estimate is $0.99 and the lowest is $0.93. Syneos Health posted earnings of $0.79 per share in the same quarter last year, which would suggest a positive year over year growth rate of 21.5%. The business is scheduled to announce its next earnings report before the market opens on Monday, January 1st.
According to Zacks, analysts expect that Syneos Health will report full year earnings of $5.13 per share for the current fiscal year, with EPS estimates ranging from $5.06 to $5.17. For the next fiscal year, analysts anticipate that the company will post earnings of $5.78 per share, with EPS estimates ranging from $5.67 to $5.89. Zacks’ earnings per share averages are a mean average based on a survey of research analysts that cover Syneos Health.
Syneos Health (NASDAQ:SYNH – Get Rating) last posted its earnings results on Thursday, February 17th. The company reported $1.36 EPS for the quarter, topping analysts’ consensus estimates of $1.34 by $0.02. The business had revenue of $1.37 billion for the quarter, compared to analysts’ expectations of $1.40 billion. Syneos Health had a net margin of 4.50% and a return on equity of 12.69%. The business’s revenue for the quarter was up 20.5% compared to the same quarter last year. During the same period in the previous year, the company posted $1.00 earnings per share.
Shares of SYNH stock opened at $80.43 on Thursday. The company has a debt-to-equity ratio of 0.82, a current ratio of 1.07 and a quick ratio of 1.07. The company’s fifty day moving average price is $80.92 and its two-hundred day moving average price is $89.72. The firm has a market capitalization of $8.25 billion, a P/E ratio of 35.91 and a beta of 1.84. Syneos Health has a 12 month low of $72.48 and a 12 month high of $104.18.
In other Syneos Health news, CAO Donna Hildebrand Kralowetz sold 1,055 shares of the stock in a transaction on Monday, January 31st. The shares were sold at an average price of $90.00, for a total transaction of $94,950.00. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.29% of the stock is owned by insiders.
Large investors have recently added to or reduced their stakes in the stock. Signaturefd LLC grew its stake in Syneos Health by 328.6% during the 4th quarter. Signaturefd LLC now owns 240 shares of the company’s stock worth $25,000 after buying an additional 184 shares during the last quarter. Clearstead Advisors LLC acquired a new position in shares of Syneos Health during the third quarter valued at $28,000. Independence Bank of Kentucky bought a new position in shares of Syneos Health during the first quarter worth about $28,000. Daiwa Securities Group Inc. increased its holdings in shares of Syneos Health by 71.0% in the 3rd quarter. Daiwa Securities Group Inc. now owns 354 shares of the company’s stock worth $31,000 after acquiring an additional 147 shares during the period. Finally, AllSquare Wealth Management LLC bought a new stake in Syneos Health in the 3rd quarter valued at about $31,000. Institutional investors and hedge funds own 94.63% of the company’s stock.
Syneos Health Company Profile (Get Rating)
Syneos Health, Inc provides biopharmaceutical outsourcing solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics in the Phase I to IV of clinical development.
- Get a free copy of the StockNews.com research report on Syneos Health (SYNH)
- Institutions And Analysts Drive UnitedHealth Group Higher
- MarketBeat: Week in Review 4/11 – 4/15
- Three Beaten Down Mega Caps The Analysts Are Upgrading
- Top 3 Safe Stocks for Conservative Investors
- Array Technologies Stock Giving Another Ground Floor Entry
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.